Microenvironment and Radiation Therapy

Dependency on tumor oxygenation is one of the major features of radiation therapy and this has led many radiation biologists and oncologists to focus on tumor hypoxia. The first approach to overcome tumor hypoxia was to improve tumor oxygenation by increasing oxygen delivery and a subsequent approach was the use of radiosensitizers in combination with radiation therapy. Clinical use of some of these approaches was promising, but they are not widely used due to several limitations. Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that is activated by hypoxia and induces the expression of various genes related to the adaptation of cellular metabolism to hypoxia, invasion and metastasis of cancer cells and angiogenesis, and so forth. HIF-1 is a potent target to enhance the therapeutic effects of radiation therapy. Another approach is antiangiogenic therapy. The combination with radiation therapy is promising, but several factors including surrogate markers, timing and duration, and so forth have to be optimized before introducing it into clinics. In this review, we examined how the tumor microenvironment influences the effects of radiation and how we can enhance the antitumor effects of radiation therapy by modifying the tumor microenvironment.

[1]  G Wiernik,et al.  Hyperbaric oxygen and radiotherapy: a Medical Research Council trial in carcinoma of the cervix. , 1978, The British journal of radiology.

[2]  G. Semenza,et al.  HIF-1, O2, and the 3 PHDs How Animal Cells Signal Hypoxia to the Nucleus , 2001, Cell.

[3]  W. Denny,et al.  Clinical Cancer esearch cer Therapy : Preclinical rmacokinetic / Pharmacodynamic Modeling Identifies 0000 and SN 29751 as Tirapazamine Analogues with roved Tissue Penetration and Hypoxic R l Killing in Tumors , 2010 .

[4]  Lei Xu,et al.  Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. , 2004, Cancer cell.

[5]  Susan M. Chang,et al.  Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. , 2004, International journal of radiation oncology, biology, physics.

[6]  P. Okunieff,et al.  Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. , 1989, Cancer research.

[7]  M. Hiraoka,et al.  Usefulness of HIF-1 imaging for determining optimal timing of combining bevacizumab and radiotherapy. , 2009, International journal of radiation oncology, biology, physics.

[8]  H. Harada How can we overcome tumor hypoxia in radiation therapy? , 2011, Journal of radiation research.

[9]  S. Dische,et al.  Hyperbaric oxygen and radiotherapy: a Medical Research Council trial in carcinoma of the bladder. , 1978, The British journal of radiology.

[10]  G. Semenza,et al.  Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. , 2000, Cancer research.

[11]  M Hiraoka,et al.  Significance of HIF-1-active cells in angiogenesis and radioresistance , 2007, Oncogene.

[12]  K. Ang,et al.  Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer. , 2004, International journal of radiation oncology, biology, physics.

[13]  L. H. Gray,et al.  The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy , 1955, British Journal of Cancer.

[14]  G. Semenza Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics , 2010, Oncogene.

[15]  K. Harrington,et al.  Effect of epoetin alfa on survival and cancer treatment-related anemia and fatigue in patients receiving radical radiotherapy with curative intent for head and neck cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Qiang Li,et al.  Recombinant Human Endostatin Normalizes Tumor Vasculature and Enhances Radiation Response in Xenografted Human Nasopharyngeal Carcinoma Models , 2012, PloS one.

[17]  M. Yoshimura,et al.  NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity , 2012, Radiation Oncology.

[18]  R. Weichselbaum,et al.  Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. , 1998, Cancer research.

[19]  Y. Kitamoto,et al.  Expression of hypoxic-inducible factor 1alpha predicts metastasis-free survival after radiation therapy alone in stage IIIB cervical squamous cell carcinoma. , 2004, International journal of radiation oncology, biology, physics.

[20]  M. Hiraoka,et al.  Treatment regimen determines whether an HIF-1 inhibitor enhances or inhibits the effect of radiation therapy , 2009, British Journal of Cancer.

[21]  J. Hanley,et al.  Hyperbaric oxygen therapy for carcinoma of the cervix--stages IIB, IIIA, IIIB and IVA: results of a randomized study by the Radiation Therapy Oncology Group. , 1981, International journal of radiation oncology, biology, physics.

[22]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[23]  M. Yoshimura,et al.  Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels , 2012, Nature Communications.

[24]  R. Weichselbaum,et al.  Combined effects of angiostatin and ionizing radiation in antitumour therapy , 1998, Nature.

[25]  T. Poskitt Radiation therapy and the role of red blood cell transfusion. , 1987, Cancer investigation.

[26]  P Vaupel,et al.  Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. , 1991, Cancer research.

[27]  I. Nagata,et al.  Protocol of radiotherapy for glioblastoma according to the expression of HIF-1 , 2006, Brain Tumor Pathology.

[28]  L. Peters,et al.  Radiation therapy with hyperbaric oxygen at 4 atmospheres pressure in the management of squamous cell carcinoma of the head and neck: results of a randomized clinical trial. , 1999, The cancer journal from Scientific American.

[29]  M Hiraoka,et al.  An antiangiogenic agent (TNP-470) inhibited reoxygenation during fractionated radiotherapy of murine mammary carcinoma. , 1997, International journal of radiation oncology, biology, physics.

[30]  mTOR in renal cell cancer: modulator of tumor biology and therapeutic target , 2009, Expert review of molecular diagnostics.

[31]  D. Hallahan,et al.  SU11248 (sunitinib) sensitizes pancreatic cancer to the cytotoxic effects of ionizing radiation. , 2007, International journal of radiation oncology, biology, physics.

[32]  M. Krause,et al.  Impact of adjuvant inhibition of vascular endothelial growth factor receptor tyrosine kinases on tumor growth delay and local tumor control after fractionated irradiation in human squamous cell carcinomas in nude mice. , 2005, International journal of radiation oncology, biology, physics.

[33]  O. Inanami,et al.  Inhibition of HIF-1α by the anticancer drug TAS106 enhances X-ray-induced apoptosis in vitro and in vivo , 2008, British Journal of Cancer.

[34]  Kiichi Hirota,et al.  Regulation of hypoxia-inducible factor 1 by prolyl and asparaginyl hydroxylases. , 2005, Biochemical and biophysical research communications.

[35]  J. Brown,et al.  Exploiting tumour hypoxia in cancer treatment , 2004, Nature Reviews Cancer.

[36]  K. Cengel,et al.  Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity. , 2008, Cancer research.

[37]  K. Ang,et al.  Endostatin improves radioresponse and blocks tumor revascularization after radiation therapy for A431 xenografts in mice. , 2007, International journal of radiation oncology, biology, physics.

[38]  G. Semenza,et al.  FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. , 2001 .

[39]  A. Koong,et al.  Loss of PTEN facilitates HIF-1-mediated gene expression. , 2000, Genes & development.

[40]  M. Hiraoka,et al.  Tumor hypoxia: A target for selective cancer therapy , 2003, Cancer science.

[41]  Jeffrey W. Clark,et al.  Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  G. Semenza,et al.  Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. , 2001, Cancer research.

[43]  G. Halliday,et al.  Role of Nicotinamide in DNA Damage, Mutagenesis, and DNA Repair , 2010, Journal of nucleic acids.

[44]  Mark W. Dewhirst,et al.  Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response , 2008, Nature Reviews Cancer.

[45]  Jie Zhang,et al.  Head and neck cancer radiosensitization by the novel poly(ADP‐ribose) polymerase inhibitor GPI‐15427 , 2009, Head & neck.

[46]  M. Dewhirst,et al.  HIF-1 and tumour radiosensitivity , 2006, British Journal of Cancer.

[47]  J. Folkman Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[48]  B. Telfer,et al.  ZD6474, a Potent Inhibitor of Vascular Endothelial Growth Factor Signaling, Combined With Radiotherapy , 2004, Clinical Cancer Research.

[49]  R. Fisher,et al.  Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  S. Li,et al.  Cancer therapeutic agents targeting hypoxia-inducible factor-1. , 2011, Current medicinal chemistry.

[51]  Robert Gray,et al.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.

[52]  B. Lu Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models: P3-030 , 2007, Clinical cancer research : an official journal of the American Association for Cancer Research.

[53]  Gerald McMahon,et al.  SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. , 2003, Cancer research.

[54]  J. Golfinos,et al.  A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma. , 2012, Journal of neurosurgery.

[55]  P. Harari,et al.  Enhancement of radiation response with bevacizumab , 2012, Journal of experimental & clinical cancer research : CR.

[56]  Y. Kakeji,et al.  Influence of an anti‐angiogenic treatment on 9L gliosarcoma: Oxygenation and response to cytotoxic therapy , 1995, International journal of cancer.

[57]  S. Leibel,et al.  The treatment of hepatic metastases from colorectal cancer with radiation therapy alone or combined with chemotherapy or misonidazole. , 1989, Cancer treatment reviews.

[58]  A. Giaccia,et al.  Hypoxic gene expression and metastasis , 2004, Cancer and Metastasis Reviews.

[59]  Judah Folkman,et al.  Thalidomide is an inhibitor of angiogenesis. , 1994 .

[60]  Michael Höckel,et al.  Detection and characterization of tumor hypoxia using pO2 histography. , 2007, Antioxidants & redox signaling.

[61]  M. Birnbaum,et al.  Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell lines. , 2005, Cancer research.

[62]  M. Hiraoka,et al.  The Akt/mTOR Pathway Assures the Synthesis of HIF-1α Protein in a Glucose- and Reoxygenation-dependent Manner in Irradiated Tumors* , 2009, Journal of Biological Chemistry.

[63]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[64]  D. Fabbro,et al.  Effect of VEGF receptor inhibitor PTK787/ZK222548 combined with ionizing radiation on endothelial cells and tumour growth , 2001, British Journal of Cancer.

[65]  Charles H. Graham,et al.  Hypoxia-driven selection of the metastatic phenotype , 2007, Cancer and Metastasis Reviews.

[66]  W. Curran,et al.  A phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies , 2011, Cancer.

[67]  J M Brown,et al.  Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation. , 1979, The British journal of radiology.

[68]  M. Lemmon,et al.  SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. , 1986, International journal of radiation oncology, biology, physics.

[69]  G. Semenza,et al.  Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1 , 1996, Molecular and cellular biology.

[70]  K. Ogasawara,et al.  A Phase II Study of Radiotherapy after Hyperbaric Oxygenation Combined with Interferon-beta and Nimustine Hydrochloride to Treat Supratentorial Malignant Gliomas , 2004, Journal of Neuro-Oncology.

[71]  L. Ellis,et al.  Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. , 2010, International journal of radiation oncology, biology, physics.

[72]  M. Dewhirst Relationships between Cycling Hypoxia, HIF-1, Angiogenesis and Oxidative Stress , 2009, Radiation research.

[73]  M. Hiraoka,et al.  Hypoxia-inducible factor 1 in tumor radioresistance , 2010 .

[74]  Huafeng Zhang,et al.  Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization , 2009, Proceedings of the National Academy of Sciences.

[75]  Michael I. Wilson,et al.  Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation , 2001, Science.

[76]  C. Wykoff,et al.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.

[77]  R. Fisher,et al.  Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  J. Cherrington,et al.  The Antiangiogenic Agents SU5416 and SU6668 Increase the Antitumor Effects of Fractionated Irradiation , 2002, Radiation research.

[79]  P. Wen,et al.  Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma. , 2010, International journal of radiation oncology, biology, physics.

[80]  Johannes H Kaanders,et al.  Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  G. Semenza,et al.  Regulation of cancer cell metabolism by hypoxia-inducible factor 1. , 2009, Seminars in cancer biology.

[82]  Jonathan Pevsner,et al.  HIF-dependent antitumorigenic effect of antioxidants in vivo. , 2007, Cancer cell.

[83]  A. Harris,et al.  Phase I/II Trial of Bevacizumab and Radiotherapy for Locally Advanced Inoperable Colorectal Cancer: Vasculature-Independent Radiosensitizing Effect of Bevacizumab , 2009, Clinical Cancer Research.

[84]  S. Heiland,et al.  Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation, and chemotherapy. , 2005, Cancer research.

[85]  Zvi Fuks,et al.  Tumor Response to Radiotherapy Regulated by Endothelial Cell Apoptosis , 2003, Science.

[86]  A. Garden,et al.  Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. , 2012, The Lancet. Oncology.

[87]  T. Golub,et al.  mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways , 2004, Nature Medicine.

[88]  R. Weichselbaum,et al.  Blockade of the Vascular Endothelial Growth Factor Stress Response Increases the Antitumor Effects of Ionizing Radiation , 1999 .

[89]  P. Hoskin,et al.  Carbogen and nicotinamide in locally advanced bladder cancer: early results of a phase-III randomized trial. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[90]  Jordi Giralt,et al.  Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. , 2010, The Lancet. Oncology.

[91]  J. Bankson,et al.  The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects , 2009, Molecular Cancer Therapeutics.

[92]  M Ancukiewicz,et al.  Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. , 2000, Cancer research.

[93]  P. Opolon,et al.  Combined effects of radiotherapy and angiostatin gene therapy in glioma tumor model. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[94]  J. Overgaard,et al.  Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. , 1996, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[95]  V. Hirst,et al.  Metabolism of SR 4233 by Chinese hamster ovary cells: basis of selective hypoxic cytotoxicity. , 1988, Cancer research.

[96]  R. Jain,et al.  Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. , 2001, Cancer research.

[97]  M. Saunders,et al.  Hypoxic radiosensitizers in radical radiotherapy for patients with bladder carcinoma , 1999, Cancer.

[98]  C. Grau,et al.  The importance of haemoglobin level and effect of transfusion in HNSCC patients treated with radiotherapy--results from the randomized DAHANCA 5 study. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[99]  A. Giaccia,et al.  Hypoxia, gene expression, and metastasis , 2007, Cancer and Metastasis Reviews.

[100]  J. Cherrington,et al.  Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response. , 2002, Cancer research.

[101]  G. Fletcher,et al.  Hyperbaric oxygen as a radiotherapeutic adjuvant in advanced cancer of the uterine cervix. Preliminary results of a randomized trial , 1977, Cancer.

[102]  M. Hiraoka,et al.  TS‐1 enhances the effect of radiotherapy by suppressing radiation‐induced hypoxia‐inducible factor‐1 activation and inducing endothelial cell apoptosis , 2008, Cancer science.

[103]  M. Dewhirst,et al.  Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. , 2004, Cancer cell.

[104]  D. Dunlop,et al.  Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[105]  W. Curran,et al.  Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[106]  Minghu Song,et al.  A mass spectrometry study of tirapazamine and its metabolites: Insights into the mechanism of metabolic transformations and the characterization of reaction intermediates , 2003, Journal of the American Society for Mass Spectrometry.

[107]  J. Greenberger Antitumor interaction of short course endostatin and ionizing radiation. , 2000, Cancer journal.

[108]  Jinho Kim,et al.  YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. , 2003, Journal of the National Cancer Institute.

[109]  G. Semenza,et al.  HER2 (neu) Signaling Increases the Rate of Hypoxia-Inducible Factor 1α (HIF-1α) Synthesis: Novel Mechanism for HIF-1-Mediated Vascular Endothelial Growth Factor Expression , 2001, Molecular and Cellular Biology.

[110]  Robert Almassy,et al.  Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. , 2004, Journal of the National Cancer Institute.

[111]  R. Johnson,et al.  Hypoxia: A key regulator of angiogenesis in cancer , 2007, Cancer and Metastasis Reviews.

[112]  M. Suntharalingam,et al.  Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03). , 2007, International journal of radiation oncology, biology, physics.

[113]  M. Barberi-Heyob,et al.  Erythropoietin-induced reduction of hypoxia before and during fractionated irradiation contributes to improvement of radioresponse in human glioma xenografts. , 2004, International journal of radiation oncology, biology, physics.

[114]  A. Gazdar,et al.  Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations. , 2009, Cancer research.

[115]  Dong-Hoon Shin,et al.  Preclinical evaluation of YC-1, a HIF inhibitor, for the prevention of tumor spreading. , 2007, Cancer letters.

[116]  P. Kristjansen,et al.  Therapeutic synergy of TNP-470 and ionizing radiation: effects on tumor growth, vessel morphology, and angiogenesis in human glioblastoma multiforme xenografts. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[117]  Rakesh K Jain,et al.  Molecular regulation of vessel maturation , 2003, Nature Medicine.

[118]  F. Baillet,et al.  Positive clinical experience with misonidazole in brachytherapy and external radiotherapy. , 1989, International journal of radiation oncology, biology, physics.

[119]  Ruud P. M. Dings,et al.  Scheduling of Radiation with Angiogenesis Inhibitors Anginex and Avastin Improves Therapeutic Outcome via Vessel Normalization , 2007, Clinical Cancer Research.

[120]  R. Cole,et al.  RACK1 Competes with HSP90 for Binding to HIF-1α and is Required for O2-independent and HSP90 Inhibitor-induced Degradation of HIF-1α , 2007 .

[121]  B. Telfer,et al.  Combining radiotherapy with AZD2171, a potent inhibitor of vascular endothelial growth factor signaling: pathophysiologic effects and therapeutic benefit , 2007, Molecular Cancer Therapeutics.

[122]  L. H. Gray,et al.  The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. , 1953, The British journal of radiology.

[123]  W. Mendenhall,et al.  Radiotherapy alone or combined with carbogen breathing for squamous cell carcinoma of the head and neck , 2005, Cancer.

[124]  D. Hallahan,et al.  Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. , 2001, Cancer research.

[125]  L. Bastholt,et al.  A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. , 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[126]  R. Stock,et al.  Phase 1 study of concurrent sunitinib and image‐guided radiotherapy followed by maintenance sunitinib for patients with oligometastases , 2009, Cancer.

[127]  Fang Li,et al.  Regulation of HIF-1α Stability through S-nitrosylation , 2007 .

[128]  M. Dewhirst,et al.  Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. , 2005, Cancer cell.

[129]  Michael Höckel,et al.  Impact of Hemoglobin Levels on Tumor Oxygenation: the Higher, the Better? , 2006, Strahlentherapie und Onkologie.

[130]  P. Harari,et al.  Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. , 1999, Cancer research.

[131]  B. Lu,et al.  Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer. , 2006, Cancer research.

[132]  C. Perez,et al.  Radiation therapy alone or combined with misonidazole in the treatment of locally advanced non-oat cell lung cancer: report of an RTOG prospective randomized trial. , 1989, International journal of radiation oncology, biology, physics.

[133]  C. Belka,et al.  The Akt-inhibitor Erufosine induces apoptotic cell death in prostate cancer cells and increases the short term effects of ionizing radiation , 2010, Radiation oncology.